FBR Opens A$2.5m Share Plan With Robotics Funding In Sight
FBR has opened a fully underwritten A$2.5 million share purchase plan to fund testing and commercialisation of its Mantis and Hadrian robotics platforms. Eligible shareholders can subscribe at the lower of A$0.115 or a discounted five-day VWAP, with one five-year option attached to each share issued.
- A$2.5 million SPP fully underwritten by Alpine Capital
- Offer price capped at A$0.115 or a 2.5% VWAP discount
- One A$0.14 option attached to each SPP share
- Funds earmarked for Mantis testing, Hadrian deployment, debt repayment and working capital
- Option issue remains subject to shareholder approval
FBR Puts A$2.5 Million Share Plan To Work
FBR Limited (ASX:FBR) has opened a fully underwritten A$2.5 million share purchase plan, giving eligible Australian and New Zealand shareholders access to the same broad funding terms as the company’s recent institutional placement. The plan is designed to support factory acceptance testing and commercial demonstrations for the Mantis welding robot, advance commercial deployment of the Hadrian platform, repay short-term debt and provide working capital.
The offer price will be the lower of A$0.115 a share and a 2.5% discount to FBR’s five-trading-day VWAP immediately before the plan closes. The fixed A$0.115 price represents a 20.9% discount to the A$0.145 last traded price cited by FBR on 2 September, alongside discounts of 18.1% to the five-day VWAP and 10.9% to the 15-day VWAP at that date.
Options Add A Second Funding Layer
Shareholders who participate will also be entitled to one option for every SPP share issued. Each option will carry a A$0.14 exercise price and expire five years after issue, but the offer will be made under a separate prospectus and requires shareholder approval, expected in November.
That structure gives participants additional potential upside if FBR’s share price exceeds the exercise price, while also creating a possible future source of dilution. The same option terms apply to the shares issued under the A$1.5 million placement announced as part of the wider A$4 million capital raising. FBR’s chief executive Mark Pivac and chief operating officer Kiel Chivers have indicated their intention to participate in the SPP.
Underwriting Secures The Target But Adds Cost
Alpine Capital is underwriting the full A$2.5 million target. If shareholder demand falls short, the underwriter must subscribe for, or procure subscriptions for, the shortfall, subject to the agreement’s conditions and FBR’s available placement capacity. That removes the immediate risk that the plan fails to reach its stated target, although the underwriting terms include a A$10,000 execution fee, a 2% management fee, a 4% selling fee and one option for every share underwritten, before GST where applicable.
FBR can accept oversubscriptions or scale back applications at its discretion. The plan is non-renounceable, participation is capped at A$30,000 per eligible shareholder across holdings, and applications cannot be withdrawn once payment is made. Those provisions matter because the final price is not fixed until the closing date and could, in principle, leave the market price below the price paid by participants when the new shares are issued.
Closing Date Sets The Next Funding Test
The SPP is scheduled to close at 5:00pm AWST on 25 September, with shares expected to be issued on 2 October and begin trading on 5 October. The options will not be issued with the shares: they remain dependent on the November shareholder vote and subsequent prospectus process.
The immediate questions are therefore participation levels, any scale-back and the final VWAP-based issue price. Beyond that, the capital raise places execution pressure on the uses FBR has identified: the market will eventually need to see whether Mantis progresses through testing and demonstrations, and whether Hadrian moves further from platform development into commercial deployment.
Bottom Line?
The funding target is protected by underwriting, but the eventual share and option count will determine how much dilution shareholders accept for FBR’s next commercialisation phase.
Questions in the middle?
- Will shareholder demand fill the SPP before Alpine Capital is required to take up any shortfall?
- What final issue price and scale-back, if any, will apply when the offer closes?
- Can Mantis testing and Hadrian deployment produce visible commercial progress before the new securities add to FBR’s capital base?